Alaunos Therapeutics, Inc. financial data

Symbol
TCRT on Nasdaq
Industry
Pharmaceutical Preparations
Location
2617 Bissonnet St, Suite 233, Houston, TX
State of incorporation
DE
Fiscal year end
December 31
Former names
ZIOPHARM ONCOLOGY INC (to 1/4/2022), EASYWEB INC (to 9/19/2005)
Latest financial report
10-K - Q4 2024 - Mar 31, 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 464 % +71%
Debt-to-equity 27.4 % -40.5%
Return On Equity -140 % +28.8%
Return On Assets -110 % +18.4%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 1.6M shares -90%
Common Stock, Shares, Outstanding 1.6M shares 0%
Entity Public Float 10.8M USD -88.6%
Common Stock, Value, Issued 2K USD 0%
Weighted Average Number of Shares Outstanding, Basic 1.6M shares +0.11%
Weighted Average Number of Shares Outstanding, Diluted 1.6M shares +0.11%

Income Statement

Label TTM Value / Value Unit Change %
Revenue from Contract with Customer, Excluding Assessed Tax 10K USD +100%
Research and Development Expense 362K USD -97.8%
General and Administrative Expense 4.46M USD -63.5%
Operating Income (Loss) -4.81M USD +86%
Nonoperating Income (Expense) 133K USD -87.7%
Net Income (Loss) Attributable to Parent -4.68M USD +86.7%
Earnings Per Share, Basic -2.92 USD/shares +86.7%
Earnings Per Share, Diluted -2.92 USD/shares +86.7%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 1.09M USD -82%
Assets, Current 2.76M USD -66.7%
Property, Plant and Equipment, Net 0 USD
Operating Lease, Right-of-Use Asset 0 USD -100%
Other Assets, Noncurrent 0 USD -100%
Assets 2.76M USD -66.7%
Accounts Payable, Current 516K USD -16.2%
Accrued Liabilities, Current 176K USD -86.9%
Liabilities, Current 692K USD -64.6%
Other Liabilities, Noncurrent 0 USD -100%
Liabilities 692K USD -64.6%
Retained Earnings (Accumulated Deficit) -920M USD -0.51%
Stockholders' Equity Attributable to Parent 2.06M USD -67.3%
Liabilities and Equity 2.76M USD -66.7%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -1.92M USD +79.6%
Net Cash Provided by (Used in) Financing Activities 0 USD
Net Cash Provided by (Used in) Investing Activities 0 USD
Common Stock, Shares Authorized 5M shares 0%
Common Stock, Shares, Issued 1.6M shares 0%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -1.92M USD +87.7%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 1.09M USD -82%
Interest Paid, Excluding Capitalized Interest, Operating Activities 0 USD -100%
Deferred Tax Assets, Valuation Allowance 213M USD +1.07%
Deferred Tax Assets, Gross 213M USD +1.07%
Depreciation 2K USD -99.7%
Payments to Acquire Property, Plant, and Equipment 0 USD -100%
Property, Plant and Equipment, Gross 15K USD 0%
Operating Lease, Liability, Current 0 USD
Operating Lease, Weighted Average Discount Rate, Percent 0 pure
Deferred Tax Assets, Operating Loss Carryforwards 155M USD +4.48%
Operating Lease, Payments 100K USD
Deferred Tax Assets, Net of Valuation Allowance 0 USD
Interest Expense 0 USD -100%